Ausgabe 1/2015
Inhalt (18 Artikel)
Tailoring treatment in myeloma: are there clues from biology?
- short review
Niklas Zojer, Heinz Ludwig
New drugs on the horizon. Treatment of myeloma in 2020, a perspective
- original report
Heinz Ludwig, Wolfgang Hilbe, Niklas Zojer
Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients
- short review
Michael Fillitz, Adelheid Seebacher, Michael Panny
To maintain or not to maintain: treatment forever in myeloma?
- short review
Wolfgang Willenbacher, Ella Willenbacher
High-dose chemotherapy and autologous hematopoietic stem cell transplantation in a myeloma patient with terminal renal failure and hepatitis C with high viral load
- case report
Niklas Zojer, Michael Gschwantler, Wolfgang Hilbe
Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia
- short review
Lukas Weiss, Thomas Melchardt, Alexander Egle
A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma
- short review
Bahil Ghanim, Mir Alireza Hoda, Thomas Klikovits, Balazs Dome, Michael Grusch, Martin Filipits, Walter Klepetko, Walter Berger, Balazs Hegedus
Optimal follow-up of ovarian cancer patients
- short review
Eduard Vrdoljak, Branka Petrić Miše, Tihana Boraska Jelavić, Snježana Tomić, Dinka Šundov, Ante Strikić
Optimal follow-up of endometrial cancer patients
- short review
Eduard Vrdoljak, Tihana Boraska Jelavić, Branka Petrić Miše
Optimal follow-up of cervical cancer patients
- short review
Eduard Vrdoljak, Tihana Boraska Jelavić, Branka Petrić Miše, Tomislav Omrčen
Radiotherapy for brain metastases: are we getting better?
- review
Leor Zach, Alisa Talianski, Yaakov Richard Lawrence
Predicting drug sensitivity by 3D cell culture models
- review
Arno Amann, Gabriele Gamerith, Julia M. Huber, Marit Zwierzina, Wolfgang Hilbe, Heinz Zwierzina
